Global Blood Therapeutics (GBT) is discontinuing an early-stage program to treat patients with idiopathic pulmonary fibrosis, a progressive and fatal lung disease.

Across two small clinical trials, Global Blood’s lead drug, GBT440, failed to raise oxygen saturation levels high enough in patients to justify moving the idiopathic pulmonary fibrosis (IPF) program forward, the company said Monday.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.